Form 4: Corbus Pharmaceuticals Director Acquires Stock Options

Director Peter Salzmann acquired 2,783 stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024.

Summary

• Peter Salzmann, a director of Corbus Pharmaceuticals Holdings, Inc., acquired 2,783 stock options on May 16, 2024.
• The options were granted at an exercise price of $45.92.
• The options vest 100% on the one-year anniversary of the grant date, May 16, 2025.
• The options expire on May 16, 2034.
• The acquisition was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.

Sentiment

Score: 7

Explanation: The document indicates a standard stock option grant to a director, suggesting confidence in the company's future. This is generally viewed as a neutral to slightly positive signal.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

Stock option grants to directors are a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• The vesting schedule of one year is fairly typical for such grants.
• Comparing the number of options granted and the exercise price to similar companies would require further analysis of their compensation structures.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates